Europe backs new leukaemia drugs from J&J and Gilead
July 25, 2014 at 07:20 AM EDT
LONDON, July 25 (Reuters) - Two new leukaemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months.
